Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shadfar Bahri

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2021
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup>Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine TumorsIrene Virgolini, Shadfar Bahri, Andreas Kjaer, et al.
Journal of Surgical Oncology|October 30, 2013
Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathologyJeon-Hor Chen, Shadfar Bahri, Rita S Mehta, et al.
NMR in Biomedicine|August 14, 2013
Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MRJeon-Hor Chen, Wei-Fan Pan, Julian Kao, et al.
Clinical Breast Cancer|March 27, 2012
Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profileAida Kuzucan, Jeon-Hor Chen, Shadfar Bahri, et al.
Radiology|September 1, 2011
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imagingJeon-Hor Chen, Shadfar Bahri, Rita S Mehta, et al.
Journal of Neuro-Oncology|March 11, 2021
Preferential tumor localization in relation to <sup>18</sup>F-FDOPA uptake for lower-grade gliomasHiroyuki Tatekawa, Hiroyuki Uetani, Akifumi Hagiwara, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 15, 2024
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysisPeter George Maliha, Masatoshi Hotta, Andrea Farolfi, et al.
Journal of Neuro-Oncology|September 15, 2020
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomasHiroyuki Tatekawa, Akifumi Hagiwara, Hiroyuki Uetani, et al.
Advances in Radiation Oncology|December 11, 2020
The Impact of <sup>18</sup>F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate CancerNeil R Parikh, Sonny Tsai, Carol Bennett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 15, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging TrialIda Sonni, Ely R Felker, Andrew T Lenis, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 3, 2021
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup>Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine TumorsIrene Virgolini, Shadfar Bahri, Andreas Kjaer, et al.
Journal of Surgical Oncology|October 30, 2013
Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathologyJeon-Hor Chen, Shadfar Bahri, Rita S Mehta, et al.
NMR in Biomedicine|August 14, 2013
Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MRJeon-Hor Chen, Wei-Fan Pan, Julian Kao, et al.
Clinical Breast Cancer|March 27, 2012
Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profileAida Kuzucan, Jeon-Hor Chen, Shadfar Bahri, et al.
Radiology|September 1, 2011
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imagingJeon-Hor Chen, Shadfar Bahri, Rita S Mehta, et al.
Journal of Neuro-Oncology|March 11, 2021
Preferential tumor localization in relation to <sup>18</sup>F-FDOPA uptake for lower-grade gliomasHiroyuki Tatekawa, Hiroyuki Uetani, Akifumi Hagiwara, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 15, 2024
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysisPeter George Maliha, Masatoshi Hotta, Andrea Farolfi, et al.
Journal of Neuro-Oncology|September 15, 2020
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomasHiroyuki Tatekawa, Akifumi Hagiwara, Hiroyuki Uetani, et al.
Advances in Radiation Oncology|December 11, 2020
The Impact of <sup>18</sup>F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate CancerNeil R Parikh, Sonny Tsai, Carol Bennett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 15, 2021
Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging TrialIda Sonni, Ely R Felker, Andrew T Lenis, et al.
Pageof 4